Caribou Biosciences (CRBU) Cash from Operations (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Operations data on file, last reported at 26984000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 26.52% year-over-year to 26984000.0 in Q1 2026; TTM through Mar 2026 was 101251000.0, a 26.48% increase from a year earlier, with the FY2025 full-year figure at 110992000.0, up 19.69% from the prior year.
• Cash from Operations for Q1 2026 stood at 26984000.0, down from 20792000.0 in the prior quarter.
• Over the last five years, Cash from Operations for CRBU reached as high as 15185000.0 in Q2 2023 and fell as low as 37203000.0 in Q1 2024.
• Historically, Cash from Operations has averaged 27084294.12 across 5 years, with a median of 26984000.0 in 2026.
• Across the five-year window, Cash from Operations sank 206.7% in 2022 and jumped 41.38% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 25044000.0 in 2022, then advanced by 14.63% to 21379000.0 in 2023, then tumbled by 65.91% to 35470000.0 in 2024, then soared by 41.38% to 20792000.0 in 2025, then fell by 29.78% to 26984000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 26984000.0 in Q1 2026, 20792000.0 in Q4 2025, and 25217000.0 in Q3 2025.